Trial | NCT02830854  Report issue

Title

Molecular Hydrogen for Cognitive Function and Performance in Elderly

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    13
A variety of non-pharmacological interventions have been used in the management of Alzheimer's disease (AD) and similar cognitive disorders in elderly, yet no therapeutic modality has demonstrated conclusive positive results in terms of effectiveness. Although it is still unknown what triggers AD, recent studies have shown that AD is associated with brain energy depletion, oxidative stress, and mitochondrial dysfunction. Since supplemental molecular hydrogen (H2) supports cell energy production and acts as a highly bioavailable mitochondria-related antioxidant, it may provide an ideal agent to facilitate treatment and perhaps prevention of AD and similar cognitive disorders in elderly. The overall hypothesis to be evaluated in this project is that administration of H2 will positively affect patient-reported outcomes and clinical biomarkers in men and women suffering from AD.
Study Started
Jul 31
2016
Primary Completion
Sep 30
2016
Study Completion
Sep 30
2016
Last Update
Oct 28
2016
Estimate

Molecular Hydrogen Experimental

Molecular hydrogen: 20 min per day of 3% H2 during 4 weeks

Criteria 

Inclusion Criteria:

Age over 65
No psychiatric comorbidities

Exclusion Criteria:

Use of dietary supplements 4 weeks before study commence
No Results Posted